HIGHLIGHTS
- who: Christian P. Kamm and colleagues from the Department of Neurology, University Bern and University of Bern, Bern, Switzerland, Department of Diagnostic and Interventional Neuroradiology have published the Article: Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial, in the Journal: PLOS ONE | www.plosone.org of January/30,/2014
- what: Atorvastatin 40 mg/d in addition to IFNB-1b did not have any beneficial effects on RRMS compared to IFNB-1b monotherapy over a period of 24 months.
- how: All patients who . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.